Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of
care in patients with EGFR mutation-positive (EGFR m+) non-small cell lung cancer …

Despite the efficacy of standard-of-care EGFR tyrosine kinase inhibitors (TKIs), erlotinib,
gefitinib and afatinib, in EGFR mutation-positive non-small-cell lung cancer, resistance …

Erlotinib (ERT), oral administration agents, is one of the most pivotal targeted drugs in the
treatment of non‐small cell lung cancer (NSCLC); however, its poor solubility, low oral …

Background: The major limitation of EGFR TKIs in EGFR-mutant lung cancer therapy is the
development of acquired resistance. The underlying mechanisms remain unknown in about …

Patients whose NSCLC tumors become afatinib resistant presently have few effective
therapeutic options to extend their survival. Afatinib resistant NSCLC cells were sensitive to …

Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib,
gefitinib, afatinib and osimertinib, are currently available for the management of EGFR …

EGFR mutations are an ongoing challenge in the treatment of NSCLC, and demand
continuous updating of EGFR TKI drug candidates. Pyrrolopyrimidines are one group of …

Gefitinib is currently the preferred treatment for non-small cell lung cancer (NSCLC) patients
with epidermal growth factor receptor (EGFR)-activating mutation. However, some patients …

The availability of several EGFR tyrosine kinase inhibitors (TKIs) for the treatment of EGFR
mutation-positive NSCLC poses important questions regarding the optimum sequence of …

Introduction: Epidermal growth factor receptor (EGFR) mutations are well-described drivers
of non-small cell lung cancer (NSCLC) and EGFR tyrosine kinase inhibitors (TKIs) have …